title: Improving bioavailability with a novel isotretinoin formulation (isotretinoin-Lidose).
abstract: Current practice guidelines recommend administration of oral isotretinoin with high-fat meals, which may pose issues with patient compliance. Isotretinoin-Lidose (Epuris™), approved by Health Canada in November 2012 and scheduled for commercial release June 2013, is based on novel lipid encapsulation technology (Lidose®) to enclose isotretinoin, thereby increasing drug absorption during fasted states. An open label, single dose randomized crossover study demonstrated pharmacokinetic bioequivalence of isotretinoin-Lidose to standard isotretinoin formulations during fed states, with significantly greater absorption during fasting. Isotretinoin-Lidose, may lead to more consistent plasma levels of isotretinoin during variable dietary conditions, providing the potential for enhanced patient outcomes.
authors.affiliation: Department of Medicine, University of Western Ontario, London, ON, Canada; Windsor Clinical Research Inc., Windsor, ON, Canada.
authors.forename: Jerry
authors.initials: J
authors.lastname: Tan
authors.forename: Sanja
authors.initials: S
authors.lastname: Knezevic
mesh_terms: D000284:Administration, Oral; D001682:Biological Availability; D002170:Canada; D003879:Dermatologic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D004041:Dietary Fats / Q000378:metabolism; D017277:Drug Approval; D005215:Fasting; D006801:Humans; D015474:Isotretinoin / Q000008:administration & dosage* / Q000493:pharmacokinetics; D008055:Lipids / Q000737:chemistry*; D055118:Medication Adherence; D013810:Therapeutic Equivalency
chemical_list: D003879:Dermatologic Agents; D004041:Dietary Fats; D008055:Lipids; D015474:Isotretinoin